The book “Regenerative Medicine: From Protocol to Patient” is edited by Dr. Gustav Steinhoff. This post has notes from the book featuring the results of some of the studies cited in the book.
• Overexpression of relaxin in C2C12/RLX myoblasts increases local MMP-2, VEGF, vascular density, and cardiac function.
• Reprogramming of mouse somatic cells to create induced pluripotent stem cells is accomplished by introducing a combination of the transcription factors Oct3/4, Sox2, Klf4, and c-Myc.
• Research found that forced expression of activating Notch intracellular domain by use of vector-8 gene transfer in the injured heart had a cardioprotective effect that prevented heart failure.
• Studies in mice and pigs have shown that cardiosphere-derived cells promote heart repair.
• Research shows that treatments that improve angiogenesis improve brain recovery after injury.
• More than 100 clinical trials are being conducted using mesenchymal stem cells.
• A study found that 30 out of 55 patients with severe acute GVHD had a complete response when treated with mesenchymal stem cells.
• Clinical gene therapy trials based on Ad5 serotype are ongoing.
• iPS-based technology has been tested to treat at least four models of disease: sickle cell anemia, Parkinson’s disease, hemophilia A, and ischemic heart disease.
• Embryonic stem cells have been approved for tests in clinical trials involving patients with spinal cord injuries.
• Patient-specific iPS cells have been generated from patients with diabetes, amyotrophic lateral sclerosis, Fanconi anemia, and myeloproliferative disorders.
• A study found that intracerebral implantation of human teratocarcinoma NT2-derived neurons led to improvement in a patients who had an ischemic infarct.
• Intravenous polyethylene glycol led to some recovery of function in dogs with spinal cord injury.
• Research shows that PDSCs are able to generate vascularized bone tissue which can be remodeled into a lamellar bone.
• A collagen sponge reinforced by a graft of poly e-caprolactone was seeded with rabbit articular chondrocytes and implanted in rats and developed a tracheal substitute.
• A tissue-engineered fibromuscular patch successfully repaired a tracheal defect in a 58-year-old man.
• A tubular tracheal matrix was successfully transplanted in a 30-year-old woman with end-stage bronchomalacia.
• A preclinical study found that injection of EPCs into the infarcted myocardium improved left ventricular function and reduced fibrosis.
• Stem cell treatment has been performed successfully in dogs with idiopathic dilated cardiomyopathy and in dogs with heart failure.
• Animal studies have found that mesenchymal stem cell transplantation increased myocardial arteriolar density in diabetic myocardium, leading to improved cardiac function.
• Intracoronary infusion of mononuclear stem cells resulted in improved cardiac function in patients with Chagas disease.
• Long-term observations after intracoronary stem cell transplantation in myocardial infarction show that treated patients have increased survival.
• The medical literature reports nearly 30 children and adults who received liver cell therapy for metabolic liver disease.
• Clinical trials are in progress to evaluate the effect of mesenchymal stem cells on renal transplantation, acute renal injury, or chronic allograph nephropathy.
